Date: 2018-05-01
Type of
information: Treatment of the first patient
phase: 2
Announcement: treatment of the first patient
Company: Galapagos (Belgium) Morphosys (Germany)
Product: MOR106
Action
mechanism: monoclonal antibody. MOR106 is a human monoclonal antibody designed to selectively target IL-17C. IL-17C has been shown to be distinct from other members of the IL-17 cytokine family and to play an important and pro-inflammatory role in certain skin disorders.
- MOR106 has been shown to potently inhibit the binding of IL-17C to its receptor and thus to inhibit its biological activity. MOR106 arises from a strategic discovery and co-development alliance between Galapagos and MorphoSys, in which both companies contribute their core technologies and expertise. Galapagos provides the disease-related biology including cellular assays and targets discovered using its target discovery platform. MorphoSys contributes its Ylanthia antibody technology to generate fully human antibodies directed against the target and contributes full CMC development of this compound.
Disease: atopic dermatitis
Therapeutic
area: Autoimmune diseases - Dermatological diseases
Country:
Trial
details:
Latest
news:
- • On May 1, 2018, Galapagos and MorphoSys announced that the first patient has been screened in IGUANA, a Phase 2 study with MOR106, an investigational antibody directed against IL-17C, in atopic dermatitis patients. At least 180 patients with moderate-to-severe atopic dermatitis (AD) are planned to be treated over a 12- week period with one of three different doses of MOR106 (1, 3 or 10 mg/kg) or placebo using two different dosing regimens in this Phase 2 trial in multiple centers across Europe. The placebo controlled, double-blind study will evaluate the efficacy, safety and pharmacokinetics (PK) of MOR106. Dosing at 2 or 4-week intervals will be evaluated over the 12-week treatment period, followed by a 16-week observation period. The primary objective will be assessed by the percentage change from baseline in Eczema Area and Severity Index (EASI) score at week 12.
Is
general: Yes
